Mariana Barros Marcondes

Mariana Barros Marcondes

Auto-generated profile, based on publicly available information

Mariana Barros Marcondes

Department of Internal Medicine, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil, unesp.br

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Clinical and Experimental Gastroenterology
Verified
Journal Article
Open access
PDF file
RBRodrigo Fedatto Beraldo
Rodrigo Fedatto Beraldo
MMMariana Barros Marcondes
Mariana Barros Marcondes
JBJúlio Baima
Júlio Baima
JBJaqueline Ribeiro Barros
Jaqueline Ribeiro Barros
MRMadhoor Ramdeen
Madhoor Ramdeen
LSLigia Yukie Sassaki
Ligia Yukie Sassaki
Background: Hidradenitis suppurativa is a chronic inflammatory skin disorder associated with inflammatory bowel disease. However, it can arise as a paradoxical side effect of anti-TNF treatment. Methods: The article reports on three patients with Crohn’s disease who developed hidradenitis suppurativa during the treatment with adalimumab. Results: Case 1: A 38-year-old female exhibited an infiltrative lesion in the inguinal region and vulva, consistent with hidradenitis suppurativa, after three months of adalimumab. These lesions were treated with partial vulvectomy. Case 2: After adalimumab treatment, a 27-year-old female, originally diagnosed with ileocolonic Crohn’s disease, went into clinical and endoscopic remission. The patient eventually presented two hyperchromic nodules in the inguinal region, which were diagnosed as hidradenitis suppurativa. The patient showed improvement after treatment with oral doxycycline and local therapy. Case 3: A 34-year-old female with fistulizing and stenosing ileocolonic Crohn’s disease, started adalimumab in 2010, with optimization in 2015. One year after, the patient developed bilateral, erythematous, hardened, inguinal nodulations with purulent drainage, consistent with hidradenitis suppurativa. Treatment with oral doxycycline, fusidic acid, and infiltration with triamcinolone resulted in partial improvement of the lesions. In 2018, the lesions deteriorate. The patient underwent surgical treatment. Conclusion: Patients with inflammatory bowel disease are more likely to the development of other mediated inflammatory diseases, such as hidradenitis suppurativa. Hidradenitis suppurativa may appear as a paradoxical reaction to anti-TNF therapy. Clinical teams must be aware of this type of complication. Early diagnosis and treatment are essential for controlling the disease and preventing the onset of complications.

23 December 2021 in Medicine
Verified
Journal Article
Open access
MAMaria Cecília de Aragão
Maria Cecília de Aragão
RBRodrigo Fedatto Beraldo
Rodrigo Fedatto Beraldo
MMMariana Barros Marcondes
Mariana Barros Marcondes
JBJaqueline Ribeiro de Barros
Jaqueline Ribeiro de Barros
GHGiédre Soares Prates Herrerias
Giédre Soares Prates Herrerias
LSLigia Yukie Sassaki
Ligia Yukie Sassaki
Rationale: Heightened inflammatory bowel disease (IBD) activity during pregnancy is associated with higher rates of preterm birth, miscarriage, and low birth weight. Therefore, its adequate treatment is essential, considering the risk–benefit of medication use. Although previous literature has described the management of IBD during pregnancy, few studies have assessed the pharmacokinetics of IBD drugs in the newborn. In this case report, we describe the management of ulcerative colitis during pregnancy and discuss the benefits of checking serum levels of infliximab in newborns exposed to the medication during pregnancy. Patient concern: A 37-year-old patient with ulcerative colitis in clinical and endoscopic remission had been undergoing treated with infliximab since 2008. The patient became pregnant in 2018. Diagnosis and intervention: Infliximab medication was discontinued at the 29th week of pregnancy. Outcomes: The pregnancy was uneventful, and the levels of infliximab in the umbilical cord were >20 μg/dL. Live vaccinations were postponed until the baby was 6 months old, when a new serum drug level proved to be undetectable. Lessons: Our case suggests that the use of infliximab is safe in pregnancy, and drug discontinuation could be considered from the 24th week of pregnancy onward to reduce placental transfer to the newborn in patients at low risk of relapse. Vaccines with live attenuated organisms should be delayed for at least 6 months or until the serum level of the medication is undetectable.

1 January 2026 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
MMMariana Barros Marcondes
Mariana Barros Marcondes
CMClara Fantinelli Moreno
Clara Fantinelli Moreno
CSCíntia Mitsue Pereira Suzuki
Cíntia Mitsue Pereira Suzuki
MRMaxwell Antonio Garcia Rodrigues
Maxwell Antonio Garcia Rodrigues
AMAlecsandro Moreira
Alecsandro Moreira
FRFernando Romeiro
Fernando Romeiro
Background: Upper gastrointestinal bleeding (UGIB) is a significant cause of cirrhosis decompensation; however, there is still controversy on risk factors for poor outcomes. This study aims to explore the impact of additional variables, such as liver disease etiology and intensive care unit (ICU) accessibility, on mortality, rebleeding, and infection rates. Methods: Cox regression analysis was employed to identify predictors associated with mortality and rebleeding, while Poisson regression analysis was utilized to assess associations with infections. Results: A total of 228 patients were included, with the majority classified as Child‐Pugh B and C. Among them, 96 patients (42.1%) had alcohol‐associated liver disease (ALD), of which 45 (46.9%) were in alcohol abstinence. One hundred and ninety‐five patients (85.5%) survived, while 33 (14.5%) died. Intubation was required for 31 patients (13.6%), and 28 were transferred to the ICU. Antibiotic prophylaxis was administered to 219 patients (96%), and 55 (24.1%) developed infections. Both orotracheal intubation and transfusions were associated with high mortality, whereas ALD was linked to a lower risk of death ( p < 0.001, 0.029, and 0.005, respectively). Intubation was also correlated with an increased risk of rebleeding, while transfer to ICU reduced this complication ( p = 0.012 and 0.045, respectively). The Child‐Pugh score and length of hospitalization were associated with the occurrence of infections ( p = 0.037 and < 0.001, respectively). Conclusions: Intubation, transfusions, liver disease etiology, and ICU accessibility are critical predictors following UGIB in cirrhosis. Additionally, the Child‐Pugh score and duration of hospitalization are directly proportional to the risk of infections in this context. Trial Registration: ClinicalTrials.gov identifier: NCT04662918